Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Amenorrhoea: endocrine causes

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Amenorrhoea with pelvic or shoulder-tip pain, vaginal bleeding, syncope or shock is ectopic pregnancy until assessed. Thunderclap headache, visual loss or ophthalmoplegia suggests pituitary apoplexy; vomiting, hypotension and electrolyte disturbance may be adrenal crisis. Use emergency pregnancy or endocrine pathways immediately rather than waiting for routine hormone results.

Synopsis

Approach absent menstruation from pregnancy and anatomy through ovarian and hypothalamic-pituitary physiology, identify urgent endocrine disease, and protect bone, endometrium and fertility while treating the cause.

  • Exclude pregnancy first in every person with pregnancy potential, regardless of stated infertility, contraception, sexual orientation or cycle irregularity.
  • Primary amenorrhoea concerns menstruation that has not begun by the age or pubertal stage in current guidance; secondary amenorrhoea is loss of established bleeding for a clinically significant interval.
  • The presence of breasts, uterus, cervix and androgen signs directs primary amenorrhoea assessment before a long laboratory list is ordered.
  • High FSH with low oestrogen indicates ovarian insufficiency, while low or inappropriately normal FSH and LH suggests hypothalamic-pituitary suppression or failure.
  • Functional hypothalamic amenorrhoea is caused by low energy availability, excessive exercise, stress or illness after alternative causes are excluded; a normal BMI does not exclude it.
  • Raised prolactin may reflect pregnancy, medicines, stress, renal disease, macroprolactin or a pituitary lesion; confirm appropriately before imaging unless mass symptoms demand urgency.
  • Hyperandrogenism with irregular cycles commonly suggests PCOS, but rapid virilisation, severe testosterone elevation and Cushing features require a different pathway.
  • Amenorrhoea on hormonal contraception may be an expected medicine effect, but new pregnancy symptoms, pain or systemic endocrine features still require assessment.
  • Management is cause specific and must protect bone during hypo-oestrogenism and endometrium during chronic anovulation, while discussing contraception and fertility explicitly.

Key red flags

Hyperprolactinaemia

Galactorrhoea, low libido, headache or visual change with suppressed gonadotrophins suggests prolactin excess, although galactorrhoea may be absent and medicine causes are common.

Primary anatomical clue

Normal breast development with absent uterus suggests Müllerian agenesis or androgen insensitivity, while cyclic pain with retained blood suggests outflow obstruction requiring gynaecological assessment.

Severe androgen excess

Rapid hair change, deep voice, clitoromegaly or marked testosterone abnormality suggests an ovarian or adrenal source rather than uncomplicated PCOS.

Pituitary or adrenal emergency

Acute headache, ophthalmoplegia, visual loss, collapse, vomiting or severe postural hypotension can indicate apoplexy or cortisol deficiency and needs immediate treatment.

Investigation priorities

01
Urine or serum beta-hCGFirst step

Exclude pregnancy before endocrine testing, imaging choices or hormone treatment.

Management branches

First stepsSecondary amenorrhoea assessment

Previously established menstruation has stopped beyond the current clinical threshold.

  1. Test for pregnancy and assess pain, bleeding, haemodynamic symptoms, contraception, lactation, medicines, weight or intake change, exercise, stress and chronic illness.
  2. Examine blood pressure, thyroid, galactorrhoea, androgen and Cushing features and signs of energy deficiency, using trauma-informed discussion of eating and pregnancy possibility.
  3. Measure FSH, LH, oestradiol, prolactin and thyroid function, adding androgen or adrenal tests when the phenotype supports them.
  4. Direct care to POI, functional hypothalamic, PCOS, prolactin, thyroid or structural pathways and plan bone or endometrial protection while definitive treatment proceeds.

Key medicines

CabergolineStart and titrate using the endocrine or fertility protocol to prolactin response and clinical goal.Nausea, postural hypotension, impulse-control effects and product-specific cardiac valve monitoring require counselling. Pregnancy and tumour plans are specialist led; do not stop antipsychotics abruptly.
LevothyroxineUse the licensed once-daily regimen titrated to thyroid tests and pregnancy-specific targets when indicated.Confirm primary versus central disease; in suspected pituitary failure assess and replace cortisol before thyroid hormone. Separate from interacting iron or calcium preparations.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CKS amenorrhoea assessmentPregnancy exclusion and gonadal, pituitary, thyroid and androgen assessment.
  • Society for Endocrinology female hypogonadism guidance2024 diagnosis and treatment of ovarian and central hypogonadism.
  • Society for Endocrinology amenorrhoea resourceMechanisms, investigations and cause-directed management.
  • NICE NG23 menopause and POI recommendationsPOI confirmation and hormone replacement.
  • NICE NG257 female fertility management2026 cabergoline and hypogonadotrophic ovulation-induction recommendations.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom